Table 2.
Financial and treatment-related factors by financial burden
| Lower financial burden % (n = 173) | Financial Toxicity % (n = 121) | p-value | |
|---|---|---|---|
| COST score | 37 ± 5 | 19 ± 6 | < 0.001 |
| History of BPH surgery | 28 (47) | 39 (47) | 0.039 |
| History of acute urinary retention | 3 (5) | 5 (6) | 0.358 |
| History of UTI | 5 (9) | 6 (7) | 0.828 |
| Evaluated by urologist in last year | 10 (18) | 6 (7) | 0.162 |
| Incontinence product utilization | |||
| Any prior incontinence use | 24 (41) | 35 (42) | 0.035 |
| Mean pads per week | 0.2 ± 1 | 0.7 ± 1 | < 0.001 |
| Mean diapers per week | 0.3 ± 1 | 0.7 ± 2 | < 0.001 |
| Mean total incontinence product per week | 0.4 ± 2 | 1.4 ± 3 | < 0.001 |
| Mean self-reported cost per week ($) | 6 ± 41 | 33 ± 91 | < 0.001 |
| Symptom scores | |||
| ICIQ-UI | |||
| Slight (≤ 5) | 17 (29) | 2 (3) | |
| Moderate (6–12) | 51 (88) | 49 (59) | |
| Severe or very severe (≥ 13) | 32 (56) | 49 (59) | < 0.001 |
| IPSS score | |||
| Mild (0–7) | 59 (102) | 17 (21) | |
| Moderate (8–19) | 31 (54) | 53 (64) | |
| Severe (≥ 20) | 10 (17) | 39 (36) | < 0.001 |
| LURN SI-10 | |||
| <7 | 29 (49) | 5 (6) | |
| ≥ 7 | 72 (124) | 95 (115) | < 0.001 |
Continuous variables expressed as mean +/- standard deviation and categorical variables as % (n). Statistical analysis performed includes 2-sample T-test or Pearson’s chi-square test respectively
Abbreviations: COST COmprehensive score for financial Toxicity, BPH Benign prostate hyperplasia, UTI Urinary tract infection, IPSS International Prostate Symptom Score, ICIQ-UI International Consultation on Incontinence Questionnaire – Urinary Incontinence), LURN SI-10 Lower urinary tract dysfunction research network symptom index-10